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Polyunsaturated fatty acids increase fibrinolytic activity of
human isolated glomeruli
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Polyunsaturated fatty acids increase fibrinolytic activity of human
isolated glomeruli. The release of plasminogen activators (PA) from
human isolated glomeruli has been studied by a sensitive radioenzy-
matic assay using '251—fibrin coated tubes and plasminogen. The glomer-
ular fibrinolytic activity (GFA) was detectable after 15 minutes of
incubation. Then it increased with time, the glomerular protein concen-
tration, and with the plasminogen concentration (P < 0.001 for all).
CaC12 (1 mM) increased the GFA (9.7 0.9 versus 4.9 0.4 tg
fibnn/mg/30 mm, P < 0.05). The GFA was also enhanced when pH
increased. Arachidonic acid (AA, 1 to 20 g/ml) increased the GFA in
a saturable manner. Inhibitors of cyclooxygenase (aspirin) or of
lipoxygenase (nordihydroguaiaretic acid) did not modify the basal and
AA-stimulated GFA. Other polyunsaturated fatty acids, such as
eicosapentaenoic acid (EPA), eicosatrienoic acid (ETA), eicosatetray-
noic acid (ETYA), or dihomo-y-linoleic acid (DHL), also stimulated the
GFA whereas linoleic acid and oleic acid did not. Polyunsaturated fatty
acids also stimulated the fibrinolytic activity of glomerular superna-
tants. Specific antibodies to t-PA, and to a lesser extent to u-PA,
decreased this fibrinolytic activity whether or not AA was added.
Furthermore, AA and EPA were found to increase the activity of
purified u-PA and t-PA. We conclude that human glomeruli release both
t-PA and u-PA, and that this release is increased by calcium and
alkaline pH. The polyunsaturated fatty acids enhanced the GFA,
mainly by a stimulatory effect of PA activity rather than an increased
release of PA from glomerular cells.
Plasmin, a serine protease, is the main fibrinolytic enzyme in
vivo. It derives from the specific cleavage of plasminogen by
plasminogen activators [1]. Two types of plasminogen activa-
tors (PA), urokinase (u-PA) and tissue—type plasminogen acti-
vator (t-PA), can be distinguished by their biochemical and
immunological properties [1, 2]. More recently, their complete
DNA sequences have been determined [3, 4]. They are synthe-
sized by a wide variety of cells and seem to play a role in
processes others than fibrinolysis: cell migration [5], hormone
processing [6], ovulation, and embryo—implantation [1, 7].
Many renal diseases are mediated, at least in part, by
coagulation and fibrin deposition [8—11], and the study of
intrarenal fibrinolysis is therefore needed. Renal tissue is
known to contain large amounts of PA, both in animal and
human species [12—17]. U-PA is mainly localized in tubular
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epithelial cells of the medulla portion of the kidney [17] and
t-PA in endothelial cells [18]. Recently we have also localized
both types of PA in isolated human glomeruli [19]. We have
shown previously that calcium and alkaline pH promoted the
PA release from rat isolated glomeruli in vitro [20]. These
factors are also known to stimulate cellular phospholipases [21]
and the release of endogenous arachidonic acid (AA) from
membrane phospholipids. Moreover, formation of thrombi in
glomeruli during thrombin infusion in vivo is associated with an
increased glomerular fibrinolytic activity [22, 23]. Thrombi
contain activated platelets which release AA metabolites [23,
241. Thus, we looked for an effect of AA and its derivatives on
the human glomerular fibrinolytic activity (GFA) in vitro.
Methods
The following materials were used: purified 125J radiolabeled
fibrinogen (Centre National de Transfusion Sanguine, Paris,
France); plasminogen (Kabi, Stockholm, Sweden); thrombin
and eicosatetraynoic acid, ETYA (Hoffmann La Roche, AG,
Basel, Switzerland); nordihydroguaiaretic acid (NDGA), aspi-
rin, arachidonic acid (AA), eicosapentaenoic acid (EPA),
eicosatrienoic acid (ETA), dihomo-y-linoleic acid (DHL),
palmitic acid, linoleic acid and linolenic acid (Sigma Chemical
Co., St Louis, Missouri, USA); indomethacin (Upjohn Co,
Kalamazoo, Mississippi, USA); polyclonal rabbit antibodies to
human t-PA and polyclonal goat antibodies to human u-PA,
prepared by ammonium sulfate precipitation; urokinase
(Choay, Paris, France); and tissue plasminogen activator puri-
fied from pig ovaries (Laboratoire d'Immunologie et Biologie,
Castres, France).
Isolated human glomeruli were obtained by differential siev-
ing and centnfugation as previously described with minor
modification [25]. Human renal cortex were obtained from five
different cadaver kidneys judged to be unsuitable for transplan-
tation. Minced renal cortex was pressed gently through succes-
sive stainless steel sieves. A 180 m sieve excluded the tubules
and blood vessels. The ifitrate was then passed through a 105
sm sieve which retained the glomeruli and allowed cells and
small debris to pass through. Glomeruli were suspended in
ice—cold Tris-HC1 buffer, pH 7.5, containing 135 mr's NaCl, 10
mM KC1, 10 m sodium acetate and 5 ms glucose, and were let
to settle for five minutes. Then the pellet, which consisted of
isolated decapsulated glomeruli with less than 2% tubular
contamination as demonstrated by light microscopy, was resus-
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pended in Tris-HCI buffer and used for studies of the glomerular
fibrinolytic activity. In some experiments, the glomerular sus-
pension was preincubated for 15 minutes with inhibitors of
cyclooxygenase and lipoxygenase, as previously reported [25,
261. Quenching experiments were performed with specific anti-
bodies to t-PA or to u-PA, added to supernatants of unstimu-
lated or AA-stimulated glomeruli.
The solid phase radioenzymatic assay used was as previously
described [20]. In brief, i25J fibrinogen, adsorbed to polystyrene
tubes at low ionic strength and treated with thrombin, served as
a substrate. The plasminogen—mediated GFA of a given glomer-
ular suspension was measured in triplicate, using the 125j
fibrin—coated tubes, in the following fashion: glomerular sus-
pensions were mixed at 0°C with plasminogen (final concentra-
tion 0.5 casein units per ml), and with or without CaCI2,
arachidonic acid or other fatty acids (final volume 100 pA per
tube). The tubes were incubated at 37°C for 30 minutes with
continuous agitation. The enzymatic reaction was stopped by
adding 1 ml of cold Tris-HC1 buffer, pH 7.5. Care was taken to
transfer completely the content of the tubes to clean tubes, and
the radioactivity was counted in a gamma counter (Searle
Analytic, Des Plaines, Illinois, USA).
Non-specific release of '251-fibrin was measured in the ab-
sence of plasminogen. This non-specific release accounted for
20 or 25% of the total release in the basal, calcium—stimulated or
alkaline conditions. It increased to 35% with addition of fatty
acids to the glomerular suspension. Ethanol (final concentration
0.25 to 0.5%), used as the vehicule for fatty acids and NDGA,
had no effect on GFA. The non-specific release was substrated
for each individual experimental point, so that the reported
GFA reflected only specific release of 1251-fibrin. The protein
Control 4.9 0.4 10.8 1.2
CaCI2 9.7 0.9c 16.2 17b
AA 12.7 2.2° 16.0 0.31
AA + CaCl2 26.2 2.7c 25.1 2.1°
content of the glomerular suspension or of glomerular superna-
tants was evaluated by the technique of Folin using bovine
serum albumin as a standard.
Statistical analysis. GFA results were expressed as micro-
grams of lysed fibrin per milligram of glomerular protein per 30
minutes. Means were compared by Student's t-test for unpaired
data. Analysis of variance or linear regression analysis were
used when appropriate.
Results
Characterization of the glomerular fibrinolytic activity (GFA)
Human GFA increased with time (Fig. 1 A) and reached a
plateau at 90 minutes in the absence or presence of calcium. By
analysis of variance, both time and calcium were shown to have
significant effects (P < 0.001, without significant interaction).
Excellent linear correlation was observed between GFA and
the glomerular protein concentration (Fig. lB. r = 0.953 with-
out, and r = 0.967 with CaC12 1 mM, P < 0.001 in both cases).
Thus, results could be expressed in rg of lysed fibrin per mg of
glomerular protein. The GFA increased in a saturable manner
(Fig. 1C) with increasing concentration of plasminogen. Maxi-
mal GFA was observed at a plasminogen concentration of 0.5
casein unit per ml with or without CaCl2,
Factors increasing the GEA
As reported in rat studies [18], calcium (Fig. 2A) and alkaline
pH (Fig. 2B) increased human GFA in vitro (Table I). By
analysis of variance, these two factors were shown to have
significant effects (P < 0.001). There was no significant inter-
action, so that their effects could be considered as independent
and additive. CaCl2 (1 mM) increased the GFA whatever was
the time of incubation but did not shorten the initial lag—phase
(Fig. 1). It increased the slope of the regression line (Fig. IB)
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Fig. 1. Enzymatic studies of the glomerular
fibrmnolytic activity as a function of the lime
(A), of the glomerular protein concentration
(B), and of the plasminogen concentration
(C). GFA was measured without (•) or with
(0) 1 mM CaCI2. Means SEM are
represented.
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Table 1. Effect of CaCI2 (1 mM) and AA (10 g/ml) on human GFA
at pH 7.5 and 8.3.a
iO—iO i10—a1 02
Calcium, mo//liter
pH 7.5 pH 8.3
Fig. 2. Stimulation of the GFA: effect of calcium (A) at pH 7.5 (closed
circles) and at pH 8.3 (0), and effect of pH (B) without (•) and with
(open circles) I m CaCI2.
a Results are expressed in J.g of lysed fibrin per mg of glomerular
____________________
protein in 30 minutes (means SEM of 12 experiments)bp<005
P< 0.001, as compared to the respective control value by Student s
t-test.
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Fig. 3. Arachidonic acid effect on the GFA at pH 7.5 (A) and at pH 8.3
(B). Experiments were performed without (S) or with (0) 1 mri CaC12.
Table 2. Effects of cyclooxygenase and lipoxygenase inhibitors on
basal and AA stimulated human GFA.
Human GFA (i.g/mg/30 mm)
Basal AA
conditions (10 gIml)
Control 4.5 0.6 10.5 1.4 P < 0.01
Indomethacin 6.7 0.9 9.7 1.1 NS
105M
Aspirin 6.1 0.5 14.0 2.6 P < 0.025
103M
ETYA 7.4 1.1" 8.3 1.0 NS
2.5. 105M
NDGA 6.0 0.9 9.9 1.3 P < 0.05
l05M
a Means SaM of six experiments are given
b P < 0.05 as compared to control basal value
between glomerular protein concentration and GFA (P <
0.001), and increased the GFA at any plasminogen concentra-
tion used (Fig. 1C, P < 0.001).
AA was a potent stimulus of human GFA at a concentration
as low as 1 pg per ml (3. l06M), and its effect reached a plateau
for a concentration of 10 to 20 g per ml (Fig. 3 and Table 1). At
pH 8.3, AA and CaCl2 had additive effects, whereas at pH 7.5
there was a potentiation of the two stimuli (significant interac-
tion by analysis of variance). Inhibition of the cyclooxygenase
pathway by aspirin 103M, or of the lipoxygenase pathway by
NDGA 105M did not modify the basal and the AA-stimulated
GFA (Table 2). The effect of AA was not statistically significant
when glomeruli were pretreated by indomethacin l0— M (P <
0.1). ETYA, 2.5.10-s M, which is an inhibitor of cyclooxygen-
ase and lipoxygenase pathways and which is a fatty acid
analogous to AA, was found to stimulate the GFA in vitro
(Table 2). Therefore we measured the effects of other fatty acids
(Table 3). We found that long carbon chain polyunsatured fatty
acids such as EPA, ETA, and DHL increased the GFA,
whereas oleic acid and linolenic acid did not.
Table 3. Effects of fatty acids (10 p.gIml) on the GFA
GFA
g/mg glomerular
protein/30 mm % of control
Control 8.5 0.5 100
AA 14.9 0.8° 175
EPA 12.9 0.9° 152
ETA 11.4 0.7" 134
DHL 15.9 1.9" 187
Oleic acid 4.6 0.4" 54
Linolenic acid 8.4 0.5 101
a Glomeruliwere incubated in Tris buffer with CaC12, 1 m. Results
(mean sEM) of six experiments are given.
b P < 0.01
° P < 0.001
Table 4. Effect of fatty acids on the fibrinolytic activity of glomerular
supernatants, of purified u-PA (10 IU/ml), and t-PA (4 IU/ml)a
Glomerular
supernatants u-PA t-PA
Control 48 4 230 30 88 7
AA 88 10° 370 40b 192 32"
EPA 92 15" 300 40 122 13"
ETA 96 8d 210 30 83 6
DHL 69 8 30 lOC 79 6
Oleic acid 66 7 160 20 62 9
Linolenic acid 79 14 230 20 84 5
Linoleic acid 63 11 260 20 87 14
Palmitic acid 54 8 180 20 56 7
a Means SEM of at least nine experiments are given, and results of
the fibrinolytic activity of the supernatants are expressed in ng of
fibrin/30 mm
b P < 0.05F < 0.01
d P < 0.001, as compared to the control value.
Fibrinolytic activity of the glomerular supernatants and of the
purified u-PA and t-PA
The fibrinolytic activity of the glomerular supernatants was
found to be significantly increased by AA, EPA and ETA (Table
4). CaC12 or alkaline pH had no significant effect. When
centrifugation was performed at 100 g for five minutes, 12,000 g
for 15 minutes and 100,000 g for one hour, the fibrinolytic
activities of the corresponding supernatants were 14.4 1.2,
13.2 1.8 and 10.2 1.2 ig fibrin/mg supernatant protein/30
mm, respectively. The stimulatory effect of AA (10 tg/ml)
added to these supernatants was still significant (26.4 3.0,
22.2 2.4, 18.0 2.4, respectively, P < 0.05).
The activity of the purified PA was also found to be increased
by AA and EPA addition (Table 4) but not by other fatty acids.
Finally, the fibrinolytic activity of the glomerular superna-
tants was decreased by pre-incubation with specific antibody to
t-PA (P < 0.05) whether AA was added or not. Similarly,
anti-u-PA antibody produced a decrease of the activity, but it
did not reach statistical significance (Table 5).
Discussion
With a sensitive radioenzymatic assay using the 125J
fibrin—coated tubes, we have demonstrated that human glomer-
10 20 10 20
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Table 5. Quenching experimcnts'
Supernatant of unstimulated
glomeruli
a Glomeruli were incubated with or without AA and then eentrifu-
gated (100 g x 5 mm). The supernatants were added to buffer or
antibody solution (final concentration anti-t-PA 0.05 mg/mI, or anti-u-
PA 0.01 mg/mI) and then tested for fibrinolytic activity. The superna-
tants of unstimulated glomeruli were tested without and with addition of
AA. Results are expressed in jig fibrin/mg protcin of supernatants/30
minutes (mean 5EM of three expcrimcnts).
b P < 0.05 as compared to results with buffer alone
uli release fibrinolytic factors in vitro. Because glomeruli con-
tain large amounts of proteolytic enzymes [27, 28], non-specific
proteolysis of fibrin was measured and substracted for each
experimental point. Quenching experiments with antibodies to
t-PA or u-PA indicated that OFA is related to PA release by
glomeruli. U-PA, although a minor component of GFA, is
positively present in the glomeruli as recently reported [191.
The low tubular contamination (less than 2%) of glomeruli
preparation can not account for the amount of the u-PA-related
activity found in the glomerular suspension. Moreover we have
shown by immunofluorescence that epithelial cells cultured
from isolated human glomeruli contain u-PA [19].
Alkaline pH and CaCI2 increased human GFA, but not the
fibrinolytic activity of the supernatants, as observed in rat
studies [201. Our findings are in accord with the well established
fact that calcium is required for exocytosis in secretory cell
system [29]. In Swiss 3T3 cells, calcium at higher concentra-
tions (3 to 4.9 mmol) has been shown to promote both produc-
tion and secretion of PA [301. Release of plasminogen activator
from the vascular wall has also been found to be calcium—
dependent when it is promoted by vasoconstrictor drugs, but
not by vasodilator drugs [311. In this study, cyclooxygenase and
lipoxygenase inhibitors, such as aspirin and NDGA, did not
modify the basal or AA-stimulated human GFA. Indomcthacin
did not modify the level of AA stimulated GFA, but seemed to
decrease the percentage of increase of the GFA after addition of
AA. Our results do not exclude that AA metabolites arc able to
stimulate the release of PA from glomerular cells as in other
cells [32—341. We have previously reported that, during
thrombin—induced intravascular coagulation, fibrin deposits oc-
curred in glomeruli and that the increase of GFA is correlated
with the release of thromboxane 132 and 12-hydroxyeicosatc-
traenoic acid, probably of platelet origin [231.
However, in our in vitro experiments, AA and olher polyun-
saturated fatty acids seemed to act on the enzymatic activity
rather than on the release of PA. Such an effect is suggested by
the increased fibrinolytic activity of glomerular supernatant
when fatty acids were added. Ultracentrifugation, which pre-
cipitated all cell and membrane components, resulted in a slight
decrease of the fibrinolytic activity but did not suppress the
effect of AA on the supernatants. Finally, AA and EPA were
also found to stimulate the activity of purified PA. It appears,
therefore, that polyunsaturated fatty acids increased the GFA
and also the apparent fibrinolytic activity of solutions of purified
t-PA and u-PA. Pre-incubation of the supernatants with anti-PA
antibodies decreased the stimulatory effect of fatty acids, which
suggests an effect of fatty acids on the glomerular PA. A
non-covalent link between other enzymes, such as renin, and
fatty acids has been demonstrated to be specific, reversible, and
determinant for the enzymatic activity [35]. It could also be due
to a more non-specific effect as that seen when detergents are
added to PA solutions [36], such as, an increase of diffusion of
an enzyme. However, the exact mechanism of action of the
fatty acids remains unclear, since all the fatly acids which
increased the fibrinolytic activity of glomerular suspension
were not found to have similar effect on glomerular superna-
tants or on purified enzymes. The effect of polyunsaturated
fatty acids on the PA release, if any, seemed low since the
magnitude of increase of the fibrinolytic activity was identical
when AA was added to glomerular suspensions or to glomerular
supernatants.
Whatever the mechanism, we demonstrated that the polyun-
saturated fatty acids increased the fibrinolytic activity of iso-
lated glomeruli by increasing the apparent activity rather than
the release of PA from glomerular cells.
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